uniQure (NASDAQ:QURE) Insider Sells 1,434 Shares of Stock

uniQure N.V. (NASDAQ:QURE) insider Walid Abi-Saab sold 1,434 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $46.86, for a total value of $67,197.24. Following the completion of the sale, the insider directly owned 168,235 shares of the company’s stock, valued at approximately $7,883,492.10. The trade was a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Walid Abi-Saab also recently made the following trade(s):

• On Friday, May 8th, Walid Abi-Saab sold 45,000 shares of uniQure stock. The stock was sold at an average price of $25.06, for a total value of $1,127,700.00.

uniQure Stock Performance

uniQure stock traded down $1.33 during mid-day trading on Tuesday, hitting $46.06. 2,046,725 shares of the company’s stock traded hands, compared to its average volume of 2,756,366. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a 50 day simple moving average of $28.45 and a two-hundred day simple moving average of $23.22. uniQure N.V. has a fifty-two week low of $8.73 and a fifty-two week high of $71.50. The stock has a market cap of $2.91 billion, a price-to-earnings ratio of -13.24 and a beta of 0.98.

uniQure (NASDAQ:QURE) last released its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, research analysts expect that uniQure N.V. will post -3.65 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

QURE has been the subject of a number of research analyst reports. Stifel Nicolaus set a $28.00 price objective on uniQure in a report on Tuesday, May 5th. Leerink Partners increased their target price on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. TD Cowen reissued a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. The Goldman Sachs Group boosted their price target on uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 18th. Finally, Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $25.00 to $65.00 in a research report on Thursday, June 18th. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $64.17.

Institutional Investors Weigh In On uniQure

Several institutional investors have recently made changes to their positions in the stock. Torren Management LLC acquired a new stake in uniQure during the fourth quarter worth approximately $28,000. IFP Advisors Inc bought a new stake in shares of uniQure during the 4th quarter valued at $48,000. Smartleaf Asset Management LLC acquired a new stake in shares of uniQure during the 4th quarter worth $48,000. CIBC Private Wealth Group LLC bought a new position in shares of uniQure in the third quarter worth $50,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of uniQure by 42.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,027 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 906 shares during the period. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.